Table 15.1.2.

Summary of General Parameters for Various EAE Adoptive Transfer Models^a

Mouse strain	Antigen specificity	Donor immunization period (days)	In vitro antigen concentration (mg/ml)	In vitro IL-12 (ng/ml)	In vitro culture Time (hr)	Number of blasts transferred (×106)	Disease type	Disease severity
SJL	PLP	7-14	50-100	—	72-96	5-10	Relapsing-remitting	Severe
	PLP139-151	7-14	20	—	72-96	1-5	Relapsing-remitting	Severe
	MBP	7-14	50-100	—	72-96	40-60	Relapsing-remitting	Moderate
	MBP84-104	7-14	50	—	72-96	10-20	Relapsing-remitting	Moderate
C57BL/6	MBP	10-14	50-100	—	72-96	50	Monophasic/chronic	Mild
	MBP84-104	10-14	50	—	72-96	50	Monophasic/chronic	Mild
	MOG	10-14	50	25	72-96	20	Chronic	Moderate
	MOG35-55	10-14	10	25	72-96	20	Chronic	Moderate
B10.PLb	MBPAc1-11	—	50	10	72	1	Monophasic	Moderate
B10.S	MBP	10-11	25	20	96	35	Monophasic	Moderate
	MBP87-106	10-11	50	20	96	35	Monophasic	Moderate

^aThese parameters have been optimized in different laboratories as previously described. SJL protocol parameters are from Pettinelli and McFarlin (1981), Pettinelli et al. (1982), Miller et al. (1991), McRae et al. (1992), Fritz and Zhao (1994), Segal et al. (1994), Skundric et al. (1993, 1994), and Tuohy and Thomas (1995). C57BL/6 protocol parameters are from Mendel et al. (1995), Shaw et al. (1995), Clark et al. (1997), Segal et al. (1998), Mendel and Shevach (2002), and Tompkins et al. (2002). B10.PL protocol parameters are from Walker and Mannie (2002). B10.S protocol parameters are from Segal and Shevach (1996).

^bNote that the B10.PL system employs T cell receptor transgenic donors which do not require in vivo priming, only in vitro culture with MBP_Ac1-11 peptide and rIL-12.